Get Ready For The Return Of The Mega-Merger, Leerink Says
Executive Summary
Following tax reform, analysts expect imminent biopharma mega-mergers, with Pfizer, Merck and Roche looking to buy, AstraZeneca, Bristol and Vertex looming as take-out candidates, and Amgen as either a buyer or a target.
You may also be interested in...
Biden Infrastructure Plan Offers Biopharma R&D Carrot, Tax Stick
Tens of billions would go to fund R&D, including Phase I and Phase II development of vaccines. But the plan would also crack down on inversions and offshoring.
Bristol/Celgene A Record-Setting Merger, If It Happens
The mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes. Celgene’s partners, and their investors, are concerned about the ramifications.
Bristol/Celgene A Record-Setting Merger, If It Happens
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.